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The molecular genetic events leading to renal cell carcinoma
(RCC) are not fully understood. Recurrent regions of deletion on
chromosomes 3p, 4q, 6q, 8p, 9p and amplifications on 17q and Xq
have been revealed by comparative genomic hybridisation (CGH)
(Verdorfer et al, 1998; Bissig et al, 1999) and loss of heterozy-
gosity (LOH) studies (Thrash-Bingham et al, 1995), as have alter-
ations on 2, 3, 9–12, 16, 17 and 18 by restriction landmark
genomic scanning (RLGS) (Cho et al, 1998a,b). The molecular
pathology of RCC varies between histopathological subtypes.
Thus chromosome 3p allele loss is the most frequent alteration in
clear cell RCC (which accounts for ~80% of tumours) but is rare in
non-clear-cell RCC. Several known and putative tumour
suppressor genes (TSGs) map to 3p and both the von
Hippel–Lindau (VHL) (Latif et al, 1993) TSG and further gene(s)
at 3p12–p21 have been implicated in clear cell RCC. VHL is
mutated, deleted or hypermethylated in up to 70% of sporadic
clear cell RCCs in addition to von Hippel–Lindau disease associ-
ated renal cell carcinoma (Prowse et al, 1997), but does not appear
to play a significant role in papillary or other non-clear-cell
cancers (Foster et al, 1994; Gnarra et al, 1994; Herman et al, 1994;
Shuin et al, 1994; Clifford et al, 1998). Inactivation of 3p12–p21
TSG(s) has been implicated in most clear-cell RCC irrespective of
VHL status, and to date no differences in molecular pathology
have been identified between clear-cell RCC with and without
VHL inactivation (Clifford et al, 1998, 1999). 
A role for the cMET gene that encodes the receptor for hepato-
cyte growth factor has been demonstrated in type 1 papillary RCC,
since constitutionally activating germline missense mutations
occur in a rare hereditary form of papillary RCC as do somatic
mutations in some sporadic cancers (Schmidt et al, 1997).
However the genes involved in the majority of non-clear-cell RCC
remain to be defined. TSC1 (van Slegtenhorst et al, 1997) and
TSC2 (European Chromosome 16 Tuberous Sclerosis Consortium,
1993) are Knudson-type TSGs that are constitutionally mutated in
the hereditary disorder tuberous sclerosis (TSC). Renal angiomy-
olipomas are found in most affected individuals, but there also
appears to be a less frequent association with RCC and several
reports have described multifocal and bilateral disease in unusu-
ally young patients, suggesting a possible role for the TSC genes
in RCC (Sampson et al, 1995; Bjornsson et al, 1996; Al-Saleem
et al, 1998). The identification of LOH or intragenic mutation
affecting the wild-type allele of TSC1 or TSC2 in TSC-associated
RCC has further supported this hypothesis (Bjornsson et al, 1996;
van Slegtenhorst et al, 1997; Al-Saleem et al, 1998). In rodent
models there is already direct evidence for a role of the TSC1 and
TSC2 orthologues in RCC. The Eker rat develops multifocal renal
cystadenoma and carcinoma and carries a truncating germline
mutation of the Tsc2 gene (Kobayashi et al, 1995). Heterozygous
engineered Tsc1 and Tsc2 knockout mice develop a similar renal
cystadenoma/carcinoma phenotype (Kobayashi et al, 1999; Onda
et al, 1999; Kwiatowski DJ, personal communication). Tumours
from the mutant animals show somatic second hit mutations of the
corresponding Tsc1 or Tsc2 wild-type allele (Yeung et al, 1995;
Kobayashi et al, 1997, 1999; Onda et al, 1999). Bi-allelic somatic
mutations of Tsc1 and Tsc2 have also been reported in chemically
induced RCCs in non-Eker rats (Urakami et al, 1997; Satake et al,
1999). However, a comprehensive study of TSC1 and TSC2 in
sporadic human RCC has not yet been reported. We therefore
undertook a systematic molecular genetic study of the TSC1 and
TSC2 genes in different types of sporadic human RCC. 
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Summary The genetic events involved in the aetiology of non-clear-cell renal cell carcinoma (RCC) and a proportion of clear cell RCC remain
to be defined. Germline mutations of the TSC1 and TSC2 genes cause tuberous sclerosis (TSC), a multi-system hamartoma syndrome that
is also associated with RCC. We assessed 17 sporadic clear cell RCCs with a previously identified VHL mutation, 15 clear-cell RCCs without
an identified VHL mutation and 15 non-clear-cell RCCs for loss of heterozygosity (LOH) at chromosomes 9q34 and 16p13.3, the
chromosomal locations of TSC1 and TSC2. LOH was detected in 4/9, 1/11 and 3/13 cases informative at both loci. SSCP analysis of the
whole coding region of the retained allele did not reveal any cases with a detectable intragenic second somatic mutation. Furthermore, RT-
PCR analysis of TSC1 and TSC2 on total RNA from 8 clear-cell RCC cell lines confirmed expression of both TSC genes. These data indicate
that biallelic inactivation of TSC1 or  TSC2 is not frequent in sporadic RCC and suggests that the molecular mechanisms of renal
carcinogenesis in TSC are likely to be distinct. © 2001 Cancer Research Campaign http://www.bjcancer.com 
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MATERIALS AND METHODS 
Tumour and constitutional DNA samples 
47 paired sporadic renal cell carcinomas and constitutional DNA
samples were studied. These comprised 17 clear-cell RCCs known
to harbour VHL mutations, 15 clear-cell RCCs in which no VHL
mutation had been detected (Foster et al, 1994; Clifford et al,
1998) and 15 non-clear-cell RCCs. All patient samples were
obtained with consent for molecular genetic analysis. 
RNA from clear cell-RCC cell lines 
Total RNA was extracted from 8 clear-cell RCC cell lines, CAKI1,
KTCL26, SKRC18, SKRC39, SKRC45, SKRC47, SKRC52 and
SKRC54 using the Qiagen RNeasy RNA extraction kit. 
LOH analysis 
7 polymorphisms at the TSC1 locus and 7 at the TSC2 locus that
we have described previously (Parry et al, 2000) were genotyped
to assay for LOH in paired tumour and constitutional DNA
samples. The TSC1 markers PM4 and PM2 are situated 50 kb and
5 kb telomeric to the gene respectively, PM1 is located in exon 9,
markers ‘exon 14’ and ‘exon 22’ are RFLPs, the intron 21 polymor-
phism is a mononucleotide repeat and PM5 is 50 kb centromeric to
the gene. The TSC2 marker LP1 is 95 kb telomeric to TSC2, IVS8
is in intron 8, LP10 is in intron 10, exon 40 contains an RFLP, Kg8
lies within the 3′ UTR of PKD1 with EJ1 and LP7 1.5 kb and
150 kb centromeric, respectively. PCR amplification of tumour
and constitutional DNA samples was carried out in parallel in
96-well microtitre plates (Hybaid). Each 50 µ l reaction contained
100 ng DNA, 25 pmoles primer (supplied by Oswel DNA
Services), 0.2 mM dNTP (Boehringer Mannheim), 5 µ l reaction
buffer (100 mM Tris pH 8.3, 500 mM KCI, 15 mM MgCl2, 0.01%
gelatin (Cetus)) and 1 U AmpliTaq Gold Polymerase (Cetus).
Cycling conditions were 94˚C 10 min, followed by 37 cycles of
annealing temperature (55–60˚C) 1 min, 72˚C 1 min, 94˚C 30 s,
and a final step of 72˚C 10 min. For autoradiography reverse
primers were end labelled with γ 33 dATP (Amersham) using T4
polynucleotide kinase (Life Technologies) according to manufac-
turers instructions and the products were electrophoresed on 6%
polyacrylamide gels (National Diagnostics). The TSC1 exon 14
1556 A/G polymorphism, the TSC1 exon 22 3050 C/T polymor-
phism and the TSC2 exon 40 1734 T/C polymorphism were
assayed by digestion of 10 µ l amplified product with the enzymes
NIaIV, HaeIII and EcoRV respectively and visualisation on 3%
agarose gels stained with ethidium bromide. LOH was determined
by visual inspection of alleles from normal and tumour DNA
samples by 3 independent observers and samples scored positive
by all observers were reamplified and assessed again. 
SSCP analysis and sequencing 
In cases exhibiting LOH at the TSC1 or TSC2 locus, all known
coding exons and exon flanking sequences of the corresponding
retained allele were screened by SSCP for evidence of intragenic
somatic mutations. Primer sequences and annealing temperatures
used are available at the Cardiff-Rotterdam Tuberous Sclerosis
Mutation Database Website (www.uwcm.ac.uk/uwcm/mg/tsc_
db/pcrpub.html). Amplification reactions were carried out as
previously described (Jones et al, 1997). SSCP was performed on
Table 1 Informativity and LOH of RCCs 
No. informative and No. showing LOH in parenthesis 
Tumour type No. TSC1 TSC2 TSC1 and TSC2
Clear cell carcinoma with a VHL mutation 17 12 (3) 14 (1) 9 (4) 
Clear cell carcinoma without a VHL mutation 15 12 (1) 14 (0) 11 (1) 
Non clear cell carcinoma 15 14 (3) 14 (0) 13 (3) 
Total 47 38 (7) 42 (1) 33 (8) 
Table 2 RCCs showing LOH in the TSC1 and TSC2 regions 
TSC1
Tumour Patient PM4 PM2 PM5 
CC-VHL mut 8 + NI + 
CC-VHL mut 10 + + NI 
CC-VHL mut 180 –– + 
CC-VHL no mut 6 NI + NI 
Non-CC 128 + NI + 
Non-CC 287 + NI NI 
Non-CC 297 + + NI 
TSC2
Tumour Patient LP1 EJ1 Kg8 LP7 
CC-VHL mut 239 – NI + NI 
CC-VHL mut – clear cell carcinoma with a mutation in the VHL gene; CC-VHL no mut – clear cell carcinoma with no identified mutation in the VHL gene;
Non-CC – non clear cell renal carcinoma; + LOH detected; – No LOH and NI not informative. Shaded boxes indicate intragenic markers. Markers
orientated from telomere towards centromere (left to right). 
PM1 Exon 14 Intron 21 Exon 22
NI NI NI NI
NI NI NI NI
NI NI – NI
NI NI NI NI
NI + NI NI
NI NI + NI
NI NI NI NI
IVS8 LP10 EXON 40
NI NI NI4 µ l PCR product diluted 1:10 with gel loading buffer (95%
formamide, 20 mM EDTA, 0.05% Bromophenol blue, 0.05%
Xylene cyanol). Samples were denatured at 94˚C for 2 min and
immediately loaded (5 h intervals) on a 0.8 mm MDE gel
(Flowgen). Electrophoresis was performed in 0.6% TBE at 20 W
for 18 h at room temperature. Products were visualised by stan-
dard silver staining (Jones et al, 1997). PCR products of samples
displaying variant band patterns were sequenced using either the
Sequenase PCR Product Sequencing kit (Amersham) or the
Thermosequenase cycle sequencing kit (Amersham). 
Reverse-transcription (RT)-PCR 
Synthesis of the first strand cDNA, was performed on 50 ng of
total RNA using the Superscript™II kit (Life Technologies). PCR
was performed using 1 µ l of the first strand cDNA product as a
template. To assess expression of TSC1, the primers TS1RTX14F
(5′ -TGGATTCTGCAAGACCATGT-3′ ) and TS1RTX14R (5′ -
CTGCTGTGGTGATCTCAGAAA-3′ ) from exon 14 were used,
for TSC2 the primers TS2RTX14F (5′ -TGCTCATCAACAGGC
AGTTC-3′ ) and TS2RTX14R (5′ -GCCACATCCCTTTCTTCCA-
3′ ) from exon 14 and TS2RTX41F (5′ -CACCGATATCTACCC-
CTCCA-3′ ) and TS2RTX41R (5′ -GACAGGCAATACCGTCCA
AG-3′ ) from exon 40 were used. 
RESULTS 
38 of the 47 RCC’s were informative for at least one marker in the
TSC1 region and seven showed LOH (Tables 1 and 2). 42 tumours
were informative for one marker or more in the TSC2 region and
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Figure 1 Representative genotypes and examples of loss of heterozygosity. (A) autoradiograph showing LOH at marker PM4 (TSC1 locus) in tumour 8. 
(B) autoradiograph showing LOH at marker PM2 (TSC1 locus) in tumour 6. (C) ethidium bromide stained agarose gel showing LOH at the TSC1 exon 14
polymorphism, E445 (1556 A >G) in tumour 128. (D) autoradiograph showing LOH at Kg8 at the TSC2 locus in tumour 239 TSC1 and  TSC2 in sporadic renal cell carcinoma  1229
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one showed LOH (Tables 1 and 2). Of the 33 tumours informative
for markers in both regions 8 showed LOH at one locus (Tables 1
and 2, Figure 1). SSCP analysis of all known coding exons (exons
3–23) and flanking intronic DNA of TSC1 in the 7 RCCs that
displayed LOH in the TSC1 region revealed an aberrant conformer
in one case, 297. However, sequencing showed this to result from
a constitutional 2 bp deletion in intron 15 at bp 2218 + 71 that was
considered likely to represent a non-pathogenic polymorphism.
SSCP analysis in tumour 128 confirmed LOH, since one allele at a
constitutionally heterozygous polymorphism in exon 14 was lost
but no other mutations were detected. SSCP analysis of the coding
exons 1–41 of TSC2 in tumour 239, that showed LOH at the TSC2
locus, did not reveal any aberrant conformers. 
RT-PCR of total RNA from each of 8 independent clear-cell
RCC cell lines confirmed expression of both TSC1 and  TSC2
(Figure 2). 
DISCUSSION 
Our data do not support a frequent role for TSC1 or TSC2 inactiva-
tion in sporadic clear-cell (with or without VHL gene inactivation)
or non-clear-cell RCC. Although LOH was observed in 5 of 20
clear-cell tumours and 3 of 13 non-clear-cell tumours informative
at both the TSC1 and TSC2 loci, apparently random allelic loss at
similar frequencies has been reported in malignant tumours of the
colon, breast and pancreas (Vogelstein et al, 1989; Seymour et al,
1994; Radford et al, 1995). The lack of detectable ‘second hits’
affecting the retained TSC1 or TSC2 allele makes the biological
relevance of LOH difficult to assess, as this frequently involves
large genomic regions that include many genes of potential impor-
tance in tumourigenesis. It remains possible that the retained TSC1
or TSC2 alleles in some of the RCCs studied may have been inac-
tivated by mutations that escaped detection, such as whole exon
deletions or by epigenetic mechanisms such as promoter methyla-
tion. However, expression of both TSC1 and TSC2 was confirmed
by RT-PCR analysis in each of 8 clear-cell RCC cell lines, ruling
out biallelic inactivation of either gene by such mechanisms in
these cases. 
Although RCC does occur in TSC it may be overdiagnosed. The
histological appearances of angiomyolipoma are very variable and
some lesions could be mistaken for atypical RCC (Pea et al, 1998).
However, careful histopathological assessment in a number of
cases showing clear cell, granular, papillary and anaplastic
morphology indicate that the association between TSC and RCC is
real (Robertson et al, 1996; Henske et al, 1998). Detailed immuno-
histochemical analysis of 6 TSC-associated RCCs has pointed to
immunophenotypic differences from the majority of sporadic
RCC, since 4 tumours (all showing regions of anaplastic ‘spindle-
cell’ morphology) displayed immunoreactivity with HMB-45, a
marker that also stains TSC-associated angiomyolipomatous and
lymphangioleiomyomatomatous lesions, but did not show
immunoreactivity for cytokeratin antibodies that are characteristi-
cally strongly positive in RCC (Robertson et al, 1996). These
differences may reflect alternative molecular mechanisms in renal
carcinogenesis in TSC-associated and sporadic RCC. Further
molecular characterisation of TSC-associated RCC should clarify
whether this is indeed the case. 
ACKNOWLEDGEMENTS 
This work was supported by Cancer Research Wales, the Tuberous
Sclerosis Association, Tuberous Sclerosis Alliance, Medical
Research Council and the Cancer Research Campaign (CRC). 
REFERENCES 
Al-Saleem T, Wessner LL, Scheitauer BW, Patterson K, Roach ES, Dreyer SJ,
Fujikawa K, Bjornsson J, Bernstein J and Henske EP (1998) Malignant
tumours of the kidney, brain and soft malignant tissues in children and young
adults with the tuberous sclerosis complex. Cancer 83: 2208–2216 
Bissig H, Richter J, Desper R, Meier V, Schrami P, Schäffer, Sauter G, Mihatsch MJ
and Moch H (1999) Evaluation of the clonal relationship between primary and
metastatic renal cell carcinoma by comparative genomic hybridisation. Am J
Path 155: 267–274 
Bjornsson J, Short MP, Kwiatkowski DJ and Henske EP (1996) Tuberous sclerosis-
associated renal cell carcinoma: clinical, pathologic and genetic features. Am J
Path 149: 1201–1208 
Cho M, Konishi N, Yamamoto K, Inui T, Kitahori Y, Nakagawa Y, Uemura H, Hirao
Y and Hiasa Y (1998a) Genomic aberrations in renal cell carcinomas detected
by restriction landmark genomic scanning. Eur J Cancer 13: 2112–2118 
Cho M, Konishi N, Kitahori Y, Hiasa Y, Nakagawa YI, Uemura H, Hirao Y and
Oosterwijk E (1998b) Detection of DNA amplification in human renal cell
carcinoma cell lines using restriction landmark genomic scanning. Cell Mol
Biol 44: 913–918 
Clifford SC, Prowse AH, Affara NA, Buys CHCM and Maher ER (1998)
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and
allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence
for a VHL-independent pathway in clear cell renal tumourigenesis. Genes
Chromosomes Cancer 22: 200–209 
Clifford SC, Walsh S, Hewson K, Brinke A, Green PM, Gianelli F, Pause A, Eng C
and Maher ER (1999) Genomic organization and chromosomal localization of
the human CUL2 gene and the role of von hippel-lindau tumor suppressor-
binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma
development. Genes Chromosomes Cancer 26: 20–28 
European Chromosome 16 Tuberous Sclerosis Consortium (1993) Identification and
characterisation of the tuberous sclerosis gene on chromosome 16. Cell 75:
1305–1315 
Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MMF, Crossey PA,
Richards FM, Cairns P, Affara NA, Ferguson-Smith MA, Buys CHCM and
Maher ER (1994) Somatic mutations of the von Hippel-Lindau disease tumour
suppressor gene in nonfamilial clear cell renal carcinoma. Hum Mol Gen 3:
2169–2173 
Gnarra JR, Tory K, Weng Y, Schnidt L, Wei MH, Li H, Latif F, Liu S, Chen F and
Duh FM (1994) Mutations of the VHL tumour suppressor gene in renal
carcinoma. Nature Genet 7: 85 
C TSC2 exon 41
B TSC2 exon 14































































Figure 2 RT-PCR amplification of TSC1 and TSC2 transcripts from 8 clear
cell RCC cell lines. Expected product sizes are indicated on the right hand
side. No RNA was added to the RT-PCR for the negative control lane 1230 L Parry et al  
British Journal of Cancer (2001) 85(8), 1226–1230 © 2001 Cancer Research Campaign
Henske EP, Thorner P, Patterson K, Zhuang ZP and Bernstein J (1998) Renal cell
carcinoma in children with diffuse cystic hyperplasia of the kidneys. Ped Dev
Path 2: 270–274 
Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Dah-Shuan RD,
Gnarra JR, Marston-Linehan W and Baylin S (1994) Silencing of the VHL
tumour-suppressor gene by DNA methylation in renal carcinoma. Proc Natl
Acad Sci USA 91: 9700–9704 
Jones AC, Daniells CE, Snell RG, Tachataki M, Idziaszczyk SA, Krawczak M,
Sampson JR and Cheadle J (1997) Molecular genetic and phenotypic analysis
reveals differences between TSC1 and TSC2 associated familial and sporadic
tuberous sclerosis. Hum Mol Gen 6: 2155–2161 
Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y and Hino O (1995) A germline
insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model
of dominantly inherited cancer. Nature Genet 9: 70–74 
Kobayashi T, Urakami S, Hirayama Y, Yamamoto T, Nishizawa M, Takahara T,
Kubo Y and Hino O (1997) Intragenic Tsc2 somatic mutations as Knudson’s
second hit in spontaneous and chemically induced renal carcinomas in the eker
rat model. Jpn J Cancer Res 59: 1206–1211 
Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O and Noda T (1999) Renal
carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a
germline Tsc2 mutation in mice. Cancer Res 59: 1206–1211 
Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I,
Modi W, Geil L, Schmidt L, Zhou FW, Li H, Wei MH, Chen F, Glenn G,
Choyke P, Walther MM, Weng YK, Duan DSR, Dean M, Glavac D, Richards
FM, Crossey PA, Fergusonsmith MA, Lepaslier D, Chumakov I, Cohen D,
Chinault AC, Maher ER, Linehan WM, Zbar B and Lerman MI (1993)
Identification of the VonHippel-Lindau disease tumor-suppressor gene. Science
260: 1317–1320 
Onda H, Lueck A, Marks PW, Warren HB and Kwiatkowski DJ (1999) Tsc2(+/–)
mice develop tumors in multiple sites that express gelsolin and are influenced
by genetic background. J Clin Invest 104: 687–695 
Parry L, Maynard JH, Patel A, Hodges AK, von Deimling A, Sampson JR and
Cheadle JP Analysis of the TSC1 and TSC2 tumour suppressor genes in
sporadic glial and glioneuronal tumours. Hum Genet 107: 350–356 
Pea M, Bonetti F, Martignoni G, Henske EP, Manfrin E, Colato C and Bernstein J
(1998) Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous
– The identification of malignant epithelioid angiomyolipoma. Am J Surg Path
22: 180–187 
Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, Affara
NA and Maher ER (1997) Somatic inactivation of the VHL gene in von
Hippel-Lindau disease tumors. Am J Hum Gen 60: 765–771 
Radford DM, Fair KL, Phillips NJ, Ritter JH, Steinbrueck T, Holt MS and
Doniskeller H (1995) Allelotyping of ductal carcinoma in situ of the breast;
deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res 55: 3399–3405 
Robertson FM, Cendron M, Klauber GT and Harris BH (1996) Renal cell carcinoma
in association with tuberous sclerosis in children. J Ped Surg 31: 729–730 
Sampson JR, Patel A and Mee AD (1995) Multifocal renal cell carcinoma in sibs
from a chromosome 9 linked (TSC1) tuberous sclerosis family. J Med Genet
32: 848–850 
Satake H, Kobayashi T, Kobayashi E, Izumi K and Hino O (1999) Isolation and
characterisation of a rat homologue of the human tuberous sclerosis gene (Tsc1)
and analysis of its mutations in rat renal cell carcinomas. Cancer Res 59:
849–855 
Seymour AB, Hruban RH, Redston M, Caldas C, Powell SM, Kinzler KW, Yee CJ
and Kern SE (1994) Allelotype of pancreatic adenocarcinoma. Cancer Res 54:
2761–2764 
Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang
ZP, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis
JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJM, Walther MM,
Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker
J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM and
Zbar B (1997) Germline and somatic mutations in the tyrosine kinase domain
of the MET proto-oncogene in papillary renal carcinomas. Nature Genet 16:
68–73 
Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y,
Kitamura H, Latif F and Zbar B (1994) Frequent somatic mutations and loss of
heterozygosity of the von Hippel-Lindau tumour suppressor gene in primary
human cell carcinoma. Cancer Res 54: 2852–2855 
Thrash-Bingham CA, Greenberg RE, Howard S, Bruzel A, Bremer M, Goll A,
Salazar H, Freed JJ and Tartof KD (1995) Comprehensive allelotyping of
human renal cell carcinomas using microsatellite DNA probes. Proc Natl Acad
Sci USA 92: 2854–2858 
Urakami S, Tokuzen R, Tsuda H, Igawa M and Hino O (1997) Somatic mutation of
the tuberous sclerosis (Tsc2) tumor suppressor gene in chemically induced rat
renal carcinoma cell. J Urol 158: 275–278 
van Slegtenhorst M, deHoogt R, Hermans C, Nellist M, Janssen B, Verhoef S,
Lindhout D, van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S,
Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell
RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Sampson JR, Reeve MP,
Richardson P, Wilmer F, Munro C, Hawkins TL, Sepp T, Ali JBM, Ward S,
Green AJ, Yates JRW, Kwiatkowska J, Henske EP, Short MP, Haines JH,
Jozwiak S and Kwiatkowski DJ (1997) Identification of the tuberous sclerosis
gene TSC1 on chromosome 9q34. Science 277: 805–808 
Verdorfer I, Culig Z, Hobisch A, Bartsch G, Hittmair A, Duba HC and Erdel M
(1998) Characterisation of a collecting duct carcinoma by cytogenetic analysis
and comparative genomic hybridisation. Int J Oncol 3: 461–464 
Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y
and White R (1989) Allelotype of colorectal carcinomas. Science 244:
207–211 
Yeung RS, Xiao GH, Jin F, Lee WC, Testa JR and Knudson AG (1995) Allelic loss
at the tuberous sclerosis 2 locus in spontaneous tumours in the Eker rat. Mol
Carcinogen 14: 28–36 